-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medicine Network September 10, as of the beginning of last month, basically all multinational pharmaceutical companies have published the semi-annual report, each company's main prescription drug products sales have slightly changed, mainly due to the second quarter of this year, the global impact of the new coronavirus epidemic increased, hospital patients in each country are decreasing, non-emergency medical and surgical delays, chronic drug prescription period, etc. , have had an impact on the sale of some products.
, for example, the hepatitis C drug market has fallen significantly as patients have fallen, as have products such as Gilead Sciences' Harvoni and AbbVie's Maviret.
In addition, the decline in infant and young child vaccinations under the outbreak is also a common phenomenon at home and abroad, in the United States market, Mercedon, Sanofi's childhood vaccines are significantly reduced compared to the same period, according to Japan's pharmaceutical economic data, Mercedon fell 31%, Sanofi decreased by 21%.
In addition to the impact of the outbreak, the accelerated launch of new biosychables has also affected sales of products such as Roche's three cancer drugs, Melohua, Hercetin and Aviva, which sold $7.74 billion worldwide in the first half of the year, down $2.53 billion from the same period last year, and is expected to see annual sales fall by more than $5 billion.
However, even though sales of Roche's three main products have declined so much, the rapid increase in sales of Tecentriq, Hemlibra, Ocrevus and others has kept Roche's total prescription drug sales growing, and small partners know that Roche now spends more than $10 billion a year on research and development, ranking first among global pharmaceutical companies, which shows how important it is to have a strong research and development pipeline.
According to Japanese pharmaceutical industry analyst Yongjiang Yantaro, in the first half of this year, drug sales reached more than 10 billion U.S. dollars, there are 14 pharmaceutical companies, the following is the specific ranking (in millions of U.S. dollars): from the table above, prescription drug sales Roche continued In first place, Novarma leapt to second place over Pfizer, mainly because sales of Pfizer's heavy-bomb drug, Lorica, plunged $1.02 billion to $710 million as it was hit by generic drug launches.
In addition, because of the completion of the acquisition of the new base, the ranking exceeded Mercado, rose to 5th place, although AbbVie also acquired Aer Jian, but because of the decline in sales of many products, so the overall growth is not much, the ranking remains unchanged, still in 7th place.
strong Hengqiang, in general, 14 multinational pharmaceutical companies, only 4 slightly declined, can maintain the current results under the epidemic, has been very good, after all, this year's visit by representatives has been greatly affected, the multinational pharmaceutical companies in this environment also have a good performance, whether it is commercial operations or product portfolio, really strong, worthy of domestic pharmaceutical companies to learn.
.